13th IMPACCT Real-World Evidence Summit
With the CMS introducing further guidance for RWD studies, the FDA announcing a new RWE center, and RWD becoming more accessible, investment has started to pour into RWE generation. All this recent excitement has confirmed that RWE will continue to play a pivotal role in drug development, yet questions still remain for the experts responsible for its application.
Returning to Boston for its 13th edition, the IMPACCT Real-World Evidence Summit remains the go-to meeting for RWE experts looking to consolidate, innovate, and optimize their RWE strategies at all stages of the drug development pipeline. Unite with 140+ senior leaders from Pfizer, Boehringer Ingelheim, Biogen, Genentech, Gilead Sciences, Kite Pharma, and Viatris, to share best practices and strategies to improve RWE accuracy, data linkage, AI, and streamline cross-functional decision making.
What Would You Miss?
- An Expanded Speaker Line-up: This year’s agenda will feature 10+ new presenting companies, including Gilead Sciences, Genentech, Ionis Pharmaceuticals, AstraZeneca, Moderna, and AbbVie.
- *NEW* Payers & Regulatory Alignment Day: Attend our new Pre-Conference Day, designed to help you stay ahead of evolving expectations from regulators, payers, and internal stakeholders.
- Real-World Case Studies: Hear emerging innovations and discuss best practices spanning tokenization, AI, data quality, and integrated planning.
- *NEW* Poster Awards Ceremony: Share your latest findings at our brand-new poster session, where the most IMPACCTful poster will be recognized with an award.
Take advantage of this opportunity to gather valuable insights from the pioneers perfecting data-quality, enhancing RWE generation, and consolidating IEPs, to transform your RWE strategy!
Quick Links: Event Guide | Register Your Place
